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Abstract  48 
Quality of life and mental health are important outcomes of bariatric therapy. This review 49 
aimed to determine endoscopic bariatric procedures impact on postprocedural quality of 50 
life and mental health. Four electronic databases were systematically searched. Studies 51 
with adults >18 years who underwent an endoscopic bariatric procedure and reported pre- 52 
and postprocedural quality of life and/or mental health using a validated tool were 53 
included. Meta-analyses were conducted RevMan and study quality was assessed. 54 
Twenty studies evaluating five different endoscopic procedures were included (N=876 55 
total sample size). Intragastric balloon placement was associated with a large 56 
improvement in postprocedural quality of life and mental health. Endoscopic bariatric 57 
therapies may improve short term quality of life and mental health alongside weight loss 58 
and comorbidity improvement.  59 
Keywords:  60 
Quality of life, mental health, endoscopic, bariatric.  61 
  62 
  63 
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Introduction 64 
Global obesity rates have nearly tripled since 1975 and have been associated with 65 
increased incidence of chronic diseases including type 2 diabetes, sleep apnoea, and 66 
cardiovascular disease [1]. Obesity and obesity-related stigmatisation also negatively 67 
impact on mental health and quality of life (QoL), particularly self-esteem, depression, 68 
anxiety, and fear of criticism by others [2, 3]. Weight loss options include traditional 69 
lifestyle approaches and bariatric surgeries, such as the gastric bypass, and more recently 70 
endoscopic weight loss procedures. These non-surgical procedures have increased from 71 
2% to 4% of all bariatric procedures from just 2014 to 2016 [4]. Whilst bariatric surgery 72 
has emerged as the most effective long-term method for weight loss, some adults do not 73 
prefer this option which is associated with surgical complications (up to 15%), morbidity 74 
(3-20%), and mortality (0.1-0.5%) [5]. Furthermore, some adults with obesity are 75 
ineligible for surgery due to operative risks, cardiovascular complications, or a BMI of 76 
<35 kg/m2 without comorbidities [6-8]. The rise in popularity of endoscopic bariatric 77 
procedures reflects their ability to meet such gaps [9, 10].    78 
Endoscopic devices currently approved by the United States Food and Drug 79 
Administration include gastric balloon (IGB) systems, gastric emptying devices, and 80 
other space occupying devices [11]. Other endoscopic bariatric therapies reported in the 81 
literature include the transoral gastroplasty, duodenal-jejunal bypass liner, and 82 
endoscopic sleeve gastroplasty (ESG) [9, 12, 13]. Mechanisms of action of these 83 
endoscopic therapies and devices include gastric restriction, malabsorption, and/or 84 
delayed gastric emptying [14].   85 
The weight loss and medical benefits of endoscopic devices have been reported; however, 86 
the impacts of endoscopic bariatric procedures on the patient-centred outcomes QoL and 87 
mental health are not as well understood [15-19]. The impact of weight loss procedures 88 
on QoL is seen by patients as a vital to a successful outcome [3]. The concept of quality 89 
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of life encompasses the physical body as well as emotional and social functioning, linking 90 
it inherently to mental health [20].  91 
As the use of endoscopic bariatric therapies is increasing internationally, there is a need 92 
to understand their full impact on candidates by looking beyond weight loss to quality of 93 
life and mental health [16, 21]. Such evidence could enhance the patient-centredness of 94 
procedure selection, care planning, and outcome evaluation [22].  95 
Research question 96 
What is the effect of endoscopic bariatric procedures on postprocedural QoL and mental 97 
health of adult patients? 98 
Method and Materials 99 
Protocol and registration 100 
A systematic review of literature was undertaken and reported according to the PRISMA 101 
guidelines [23]. The protocol was prospectively registered with the International 102 
Prospective Register for Systematic Reviews (PROSPERO number: 103 
CRD42020159822).      104 
Eligibility criteria 105 
Studies which included adults >18 years who elected an endoscopic bariatric procedure 106 
were eligible if they measured pre- and postprocedural QoL or mental health via a 107 
validated tool. The following endoscopic bariatric therapies were included in this review: 108 
ESG, IGB, transpyloric shuttle (TPS), primary obesity surgery endoluminal (POSE), 109 
duodenal-jejunal bypass liner (DJBL), aspiration therapy, duodenal mucosal resurfacing, 110 
incisionless anastomosis, overstitching endoscopic suturing system, transoral 111 
gastroplasty, and transoral endoscopic restrictive implant system. Studies were excluded 112 
when endoscopic therapy data was merged with excluded therapies including medical, 113 
lifestyle, and/or surgical weight loss. This review considered original research studies 114 
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including prospective and retrospective observational studies and intervention studies; 115 
studies were not limited by publication date. Each eligible arm of an intervention study 116 
was considered alone (i.e. not in relation to the comparator group) as representing 117 
prospective cohort data. Intervention study arms (whether comparator or intervention) 118 
which provided additional counselling and/or postprocedural variations in support 119 
beyond usual care, which would affect QoL and mental health outcomes, were excluded. 120 
Studies were sourced in any language if they could be translated to English using Google 121 
Translate [24]. Excluded publication types were conference abstracts or papers, reviews, 122 
study protocols, cross-sectional studies, and qualitative studies.     123 
Search strategy and study selection 124 
Studies were searched in the electronic databases: EMBASE, Medline, CINAHL, and 125 
PsycINFO. The search strategy comprised a combination of controlled vocabulary and 126 
keywords (Table S1). The search strategy was designed in PubMed and translated into 127 
other databases using the Systematic Review Accelerator Polyglot Search [25]. A 128 
structured sensitivity analysis of the search strategy was undertaken in EMBASE and 129 
CINAHL. When studies were irretrievable corresponding authors were contacted. Alerts 130 
for new studies were set up across databases, with any new eligible studies included up 131 
until 21st March 2020. Reference lists of relevant papers were hand searched to identify 132 
additional studies. Systematic search results were de-duplicated with Systematic Review 133 
Accelerator De-Duplicate software [25, 26]. Covidence software was utilized for 134 
screening of title/abstract and full text and was undertaken independently by two 135 
reviewers (AM and NG) [27]. A third reviewer (SM) assisted with eligibility 136 
disagreements. Corresponding authors were contacted for studies requiring further 137 
information to determine eligibility.  138 
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Outcomes 139 
Outcomes were QoL, depression, anxiety, and mood. Outcomes which were considered 140 
as confounding variables on the primary outcomes included: changes in body 141 
composition (excess weight loss [EWL], body mass index [BMI], total body weight, fat 142 
mass, or waist circumference), changes in incidence or prevalence of comorbidities, and 143 
peri- and postprocedural adverse events.  144 
Data extraction 145 
Data were extracted a single investigator (AM or NG) and checked for accuracy by a 146 
second (JH, BFK, or IM). Any corrections to extracted data by the second reviewer were 147 
verified by a third investigator (NG or AM). For studies with missing data, corresponding 148 
authors were contacted. Where data on the same study variable was reported in multiple 149 
publications, the data extracted comprised either the most complete data (e.g. that which 150 
reported variance), data representing intention to treat analysis, or the largest sample size. 151 
Data reported in graphical form was extracted via Web Plot Digitizer software [28].    152 
Quality assessment and risk of bias  153 
Included articles were critically appraised by two investigators independently (AM and 154 
NG) using the Academy of Nutrition and Dietetics Quality Criteria Checklist [29]. 155 
Studies were rated as positive, neutral, or negative quality based on the internal risk of 156 
bias. Disagreements were resolved through discussion until consensus was reached and 157 
decision making was reviewed by a third authors (SM).  158 
GRADEpro software was used to rate the confidence in the body of evidence for all 159 
studies with a primary outcome. Confidence in the body of evidence considered study 160 
design, risk of bias, consistency, directness, publication bias, effect sizes, and precision 161 
according to the Grading of Recommendations Assessment, Development and Evaluation 162 
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methodology (GRADE) approach (Table S4) [30]. GRADE was completed initially by 163 
AM and through consensus of three authors (AM, NG, SM).   164 
Meta-analytical approach 165 
Ccontinuous data were pooled using the inverse variance test using RevMan (Review 166 
Manager 5, Version 5.3) [31]. The total QoL score was prioritized and when not available, 167 
general health domain was used. When standard deviations were not reported, a 168 
calculation was made using the RevMan Calculator (Review Manager 5, Version 5.3). If 169 
data were presented as median (interquartile range), the distance between the interquartile 170 
range was assumed to be 1.35 standard deviations [32]. Outcomes were reported as 171 
standardized mean differences (SMD) to account for the different tools used to measure 172 
each construct. A random effects model was used across all meta-analytical models 173 
representing the substantial clinical heterogeneity expected. Studies were assessed for 174 
statistical consistency using the I2 statistic. High levels of statistical inconsistency were 175 
explored using confounding variables, outlier results, or sample characteristics in a 176 
sensitivity analysis.  177 
Results 178 
Search results and study characteristics  179 
The search strategy retrieved 5,959 records, 338 records were full text screened for 180 
eligibility, and 20 papers were included (Figure 1). Two additional records were identified 181 
through snowballing. The main reason for exclusion was study design (n=146) and 182 
surgical bariatric therapy (n=134). 183 
The 20 studies were published between 2008 and 2019 with a total number of 876 patients 184 
(77% female). Intragastric balloons were the predominant endoscopic therapy (n=14) [2, 185 
20, 33-45], followed by aspiration therapy (n=2) [46, 47], TOGA (n=2) [12, 48], ESG 186 
(n=1) [13], and TPS (n=1) [49] (Table S2).  187 
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Most studies were observational studies (n=15), with the remainder being randomised 188 
controlled trials (RCTs) (n=5). All studies were rated as positive quality (n=9) or neutral 189 
quality (n=11) (Table S3). The most common reasons for downgrading the quality of 190 
studies were failing to report eligibility criteria or sampling method, insufficient duration 191 
of intervention, or failure to account for confounding factors in the statistical analysis. 192 
The overall GRADE for QoL and mental health was “low” and “very low” due to the 193 
majority of the studies using a prospective observational design as opposed to randomised 194 
controlled trials, some risk of bias, and statistical inconsistency (Table S4).  195 
Endoscopic bariatric therapies’ impact on quality of life 196 
All but one study measured QoL (n=19 studies) using a range of tools (Table 1). Eighteen 197 
studies reported a statistically significant improvement in QoL from baseline to follow-198 
up, with only one study showing no change [44]. Interestingly, three studies appear to 199 
have misinterpreted their QoL results [36, 39, 42]. 200 
Nine studies with a total of 371 participants (n=350 at follow-up) who underwent IGB 201 
(6- to 76-month follow-up) were included via meta-analysis. Intragastric balloon 202 
placement was associated with a significant improvement in QoL (SMD:0.78; 95%CI: 203 
0.56,1.00; P=0.05; I2: 48%). A sensitivity analysis identified that results from De Castro 204 
et al 2010  [44] impacted on the overall I2 and was removed in sensitivity analysis on the 205 
basis of QoL construct differences. Specifically, De Castro et al 2010 [44] used the GIQLI 206 
tool which assesses gastrointestinal-related QoL whereas other studies assessed general 207 
health-related QoL. Following sensitivity analysis, IGB placement was associated with a 208 
large improvement in postprocedural QoL (SMD: 0.85; 95%CI: 0.69, 1.02; P<0.00001; 209 
I2: 7%; Figure 2). Insufficient data prevented other endoscopic bariatric therapies’ impact 210 
on QoL being pooled via meta-analysis. It was not possible to assess publication bias due 211 
to small number of studies included in the meta-analysis. 212 
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 Endoscopic bariatric therapies’ impact on mental health 213 
Depression, anxiety, and/or mental health including psychological or emotional health 214 
were assessed in seven studies, six of which excluded patients with psychiatric disorders 215 
or those taking anti-depressants [2, 41, 42, 45-47]. (Table S2). All studies reported a 216 
statistically significant postprocedural improvement in mental health. Five IGB studies 217 
were pooled via meta-analysis (n=367 participants at 6 to 76-months follow-up), finding 218 
that IGB was associated with a large improvement in the mental health, depression, or 219 
anxiety (SMD: 0.86; 95%CI: 0.29, 1.42; P=0.003; I2=92%; Figure 3). Insufficient data 220 
prevented other endoscopic bariatric therapies’ impact on mental health being pooled via 221 
meta-analysis. It was not possible to assess publication bias due to small number of 222 
studies included in the meta-analysis. 223 
Impact of confounding factors on quality of life and mental health 224 
All studies in the meta-analysis were neutral quality except two studies [2, 20]. Studies 225 
reporting the most significant changes in QoL and mental health were rated neutral [34, 226 
40]. All studies reported a significant decrease in weight as changes to total body weight, 227 
BMI, TBWL%, or EWL%. The two studies (Guedes et al 2019 and Deliopoulo et al 2013) 228 
with the largest improvements in mental health also had the greatest weight loss [40, 43]; 229 
however, associations with strength of weight loss and change in mental health were not 230 
consistent thereafter. The largest improvements in QoL did not coincide with the highest 231 
mean weight loss. Guedes et al 2019 [40] reported the largest weight loss but only a small 232 
improvement in QoL. However, Tayyem et al 2014 [34] and Fuller et al 2013 [42] had 233 
slightly less but very similar weight loss to Guedes et al 2019 [40] and reported the most 234 
significant improvements in QoL. 235 
Improvements in one or more comorbidities at follow-up were reported in nine studies 236 
including significant improvements and/or remission of type II diabetes mellitus, 237 
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hypertension, obstructive sleep apnoea, and metabolic syndrome [12, 13, 20, 33, 39-41, 238 
46-48]. Studies that reported comorbidity risk factors (blood pressure, HbA1c, 239 
triglycerides, or LDL cholesterol) also reported improvements (Table S2). Three studies 240 
did not report follow-up comorbidity data (34, 40, 48). No association was seen between 241 
improvements in comorbidities and improvements in QoL or mental health.  242 
Adverse events were reported categorically as ordinal or nominal variables or as a reason 243 
for study withdrawal in 13 studies [2, 20, 33, 36-39, 41, 42, 44, 46-49]. The most common 244 
adverse events were nausea and vomiting. Early balloon removal occurred in three 245 
studies: 1.2% in Alfredo et al 2014 [41], 3.4% in Mui et al 2010 [20] and 22% in Guedes 246 
et al 2017 [2]. Although the impact of adverse events on QoL in De Castro et al 2010 [44] 247 
was evident, there was no other clear associations found between adverse events and 248 
mental health or QoL. 249 
The amount and type of multidisciplinary support provided to patients varied and was 250 
only reported in 10 of the 20 studies [2, 20, 37-39, 41-43, 46, 47]. Types of support 251 
included: unlimited 24 hour phone support [43], follow-up with a dietitian [2, 20, 41, 43], 252 
nutrition counselling [38, 39, 47], cognitive behavioural therapy [47], and/or a lifestyle 253 
modification program [42, 46]. Studies with the most significant improvements in mental 254 
health and QoL provided patients with the most support [2, 20, 42, 43] 255 
Discussion 256 
This systematic review and meta-analysis evaluated the effects of endoscopic bariatric 257 
procedures on postprocedural QoL and mental health using mostly observational 258 
evidence. Qualitative synthesis found strong and consistent improvements in QoL (95% 259 
of studies) and mental health (100% of studies). Meta-analyses of IGB studies also 260 
showed large statistically significant improvements in QoL and mental health. Pooled 261 
findings showed strong consistency for QoL; however, there was statistical inconsistency 262 
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in pooled effects on mental health, likely due to slight differences in the concepts included 263 
in mental health assessment tools.  Although pooled effect sizes were large for the impact 264 
of IGB on postprocedural QoL and mental health; confidence in the body of evidence was 265 
low and very low respectively, where main reasons for downgrading were related to risk 266 
of bias in the included studies and the observational study design, highlighting the need 267 
for further RCTs.  268 
A systematic review by Lindekilde et al [50] evaluated the impact of any bariatric 269 
procedure (mostly surgical, two were endoscopic), reporting similar improvements in 270 
postprocedural QoL. The previous review found an association of positive changes in 271 
QoL with higher weight loss [50]. However, the current review did not find a consistent 272 
positive association between weight loss and quality of life. The drivers of improvements 273 
in QoL following endoscopic bariatric procedures may be necessarily be due to the 274 
amount of weight loss alone and is likely to also reflect changes in physical appearance 275 
and physical function, general health through improvements in comorbidities, and social 276 
functioning due to increased confidence [12, 35]. Although this study did not identify an 277 
association between quality of life or mental health with improved comorbidities, this is 278 
likely a reflection of comorbid outcomes being inconsistently measured. Gastrointestinal-279 
related QoL seems to differ from other postprocedural QoL domains. This review found 280 
much smaller and/or no improvements in gastrointestinal-related QoL, likely related to 281 
commonly reported gastrointestinal adverse events by studies using endoscopic bariatric 282 
procedures [50].  283 
The reported improvements in mental health found in this review also align with the 284 
findings of Dawes et al [51], which evaluated the impact of bariatric surgery on mental 285 
health. Spirou et al [16] also found similar results at six-months postoperative; although, 286 
results at >36-months showed a reduction in mental health improvements. These findings 287 
suggested that QoL and mental health improvements may not be retained long-term and 288 
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may be due to a ‘psychological honeymoon period’ due to initial weight loss [16]. This 289 
may be translatable to endoscopic bariatric procedures, many of which are temporary. An 290 
association with weight change and mental health was identified in this review, which is 291 
inconsistent with previous research. Results suggest the amount of weight lost positively 292 
impacted participants mental health change; each study displayed a significant decrease 293 
in weight following endoscopic procedures. Canetti et al [52] analysed the change in 294 
mental health and QoL in Silastic Ring Vertical Banded Gastroplasty (laparoscopic) 295 
patients. Findings showed even though weight loss at 10-years was maintained, 296 
improvements in mental health were not.  297 
The study with the most significant improvement in mental health and weight loss offered 298 
24-hour telephone support and monthly dietitian follow-ups. A recent systematic review 299 
and meta-analysis found that compared with standard multidisciplinary care, intensive 300 
pre- and/or postoperative psychological intervention resulted in significantly improved 301 
postoperative symptoms of depression and anxiety [53]. This suggests that while bariatric 302 
procedures, whether endoscopic or surgical, may improve mental health at least 303 
temporarily, the greatest improvements are seen with intensive multidisciplinary support, 304 
aligning with bariatric clinical practice guidelines [54]. 305 
Limitations 306 
Meta-analysis was limited by the number of diverse endoscopic procedures which have 307 
measured and adequately reported postprocedural QoL and mental health. Conclusions 308 
are also limited by the short duration of follow-up; meaning results cannot be interpreted 309 
to represent long-term outcomes. The meta-analysis was unable to control for variations 310 
of the effect of the procedure and confounding characteristics [55]. The exclusion of 311 
patients with psychiatric disorders or those taking anti-depressants limits the 312 
generalisability of the findings on mental health. Confidence that the estimated pooled 313 
means reflect the true change in QoL and mental health is low and very low. Therefore, 314 
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findings must be interpreted with the understanding that they may change with the 315 
availability of higher quality evidence, such as that from well conducted RCTs with 316 
adequate blinding and length of follow-up. 317 
Implications for future practice and research 318 
Health professionals should recognise the importance of QoL and mental health to 319 
patients and provide multidisciplinary support in line with the latest clinical practice 320 
guidelines [55], which includes dietetic and psychological intervention. Future research 321 
should be improved by strengthening the reporting of methods and results by utilising 322 
validated checklists such as the STROBE checklist for observational studies [56]. Studies 323 
should also seek to always contain patient-centred outcomes such as QoL, mental health, 324 
and the effects of weight stigmatisation in addition to clinical weight loss and medical 325 
outcomes. Consideration should be given to the reporting of results, including the 326 
reporting of baseline, change, and follow up measures of central tendency and variance, 327 
and not report results only graphically. Future research should incorporate QoL and 328 
mental health as an integral outcome of therapy success with further examination of 329 
weight-stigma.  330 
Conclusion 331 
Endoscopic bariatric procedures, particularly IGB, may improve postprocedural QoL and 332 
mental health alongside weight loss and comorbidity improvements; however, their effect 333 
on long term QoL and mental health is unknown. Multidisciplinary support by dietitians 334 
and/or psychologists is important for optimising QoL and mental health outcomes. 335 
Further research is required to understand the impact of diverse types endoscopic bariatric 336 
procedures on QoL and mental health in the long term.  337 
Ethical approval 338 
15 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
This article does not contain any studies with human participants or animals performed 339 
by any of the authors. 340 
Conflict of interest 341 
The authors declare there are no conflict of interest. 342 
 343 
Abbreviations 344 
BAROS, Bariatric Analysis and Reporting Outcome System 345 
BQL, Body Quality of Life 346 
DJBL, Duodenal-jejunal bypass liner 347 
ESG, Endoscopic Sleeve Gastroplasty 348 
EWL, Excess Weight Loss 349 
FDA, Food and Drug Administration  350 
GIQLI, Gastrointestinal Quality of Life 351 
IGB, Intragastric Balloon 352 
OR, Odds Ratio 353 
POSE, Primary obesity surgery and endoluminal 354 
QoL, Quality of life 355 
SF-36, Short Form Health Survey 356 
SMD, Standardised Mean Difference 357 
TPS, Transpyloric Shuttle 358 
16 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
 359 
Conflict of interest 360 
The authors declare there are no conflict of interest. 361 
Ethical approval statement 362 
This article does not contain any studies with human participants or animals performed 363 
by any of the authors. 364 
Informed consent. 365 
Informed consent does not apply.366 
17 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
References 
1. World Health Organization. Obesity and overweight. . Available from: 
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Published 
2018. Acessed November 11, 2019. 
2. Guedes, E., et al., Impact of 6 months of treatment with intragastric balloon on body 
fat and quality of life in obese individuals with metabolic syndrome. Health and 
Quality of Life Outcomes, 2017. 15(1): p. 1-6. 
3. Sierżantowicz, R., et al., Effect of BMI on quality of life and depression levels after 
bariatric surgery. Advances in clinical and experimental medicine : official organ 
Wroclaw Medical University, 2017. 26(3): p. 491. 
4. Angrisani, L., et al., IFSO Worldwide Survey 2016: Primary, Endoluminal, and 
Revisional Procedures. Obesity Surgery, 2018. 28(12): p. 3783-3794. 
5. Buchwald, H., et al., Bariatric surgery: A systematic review and meta-analysis. Jama-
Journal Of The American Medical Association, 2004. 292(14): p. 1724-1737. 
6. Regan, J., et al., Early Experience with Two-Stage Laparoscopic Roux-en-Y Gastric 
Bypass as an Alternative in the Super-Super Obese Patient. Obesity Surgery, 2003. 
13(6): p. 861-864. 
7. Schwartz, A., L. Etchechoury, and D. Collet, Outcome after laparoscopic gastric 
bypass for super-super obese patients. Journal of Visceral Surgery, 2013. 150(2): p. 
145-149. 
8. Villamere, J., et al., Body mass index is predictive of higher in-hospital mortality in 
patients undergoing laparoscopic gastric bypass but not laparoscopic sleeve 
gastrectomy or gastric banding. American Surgeon, 2014. 80(10): p. 1039-1043. 
9. Behary, J. and V. Kumbhari, Advances in the Endoscopic Management of Obesity. 
Gastroenterology Research and Practice, 2015. (2015): 1-9. 
18 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
10. Abu Dayyeh, B.K., et al., ASGE Bariatric Endoscopy Task Force systematic review 
and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic 
bariatric therapies. Gastrointest Endoscopy, 2015. 82(3): p. 425-38.e5. 
11. FDA (Food and Drug Adminitsration). Weight-Loss and Weight Management 
Devices. 2019  [cited 2020 11-03]; Available from: https://www.fda.gov/medical-
devices/products-and-medical-procedures/weight-loss-and-weight-management-
devices#loss. 
12. Familiari, P., et al., Transoral gastroplasty for morbid obesity: a multicenter trial with 
a 1-year outcome. Gastrointestinal Endoscopy, 2011. 74(6): p. 1248-1258. 
13. Fiorillo, C., et al., 6-Month Gastrointestinal Quality of Life (QoL) Results after 
Endoscopic Sleeve Gastroplasty and Laparoscopic Sleeve Gastrectomy: A Propensity 
Score Analysis. Obes Surg, 2020. 
14. Jason, B. and K. Vivek, Advances in the Endoscopic Management of Obesity. 
Gastroenterology Research and Practice, 2015. 2015(2015). 
15. Saber, A.A., et al., Efficacy of First-Time Intragastric Balloon in Weight Loss: a 
Systematic Review and Meta-analysis of Randomized Controlled Trials. Obes Surg, 
2017. 27(2): p. 277-287. 
16. Spirou, D., J. Raman, and E. Smith, Psychological outcomes following surgical and 
endoscopic bariatric procedures: A systematic review. Obes Rev, 2020. 
17. Yorke, E., et al., Intragastric Balloon for Management of Severe Obesity: a 
Systematic Review. Obes Surg, 2016. 26(9): p. 2248-2254. 
18. Fernandes, M.A.P., et al., Intragastric balloon for obesity. Cochrane Database of 
Systematic Reviews, 2007(1). 
19 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
19. Szmulewicz, A., et al., Mental health quality of life after bariatric surgery: A 
systematic review and meta-analysis of randomized clinical trials. Clinical obesity, 
2019. 9(1): p. e12290. 
20. Mui, W., et al., Impact on Obesity-Related Illnesses and Quality of Life Following 
Intragastric Balloon. Obesity Surgery, 2010. 20(8): p. 1128-1132. 
21. NCE (National Institute for Health and Care Excellence) Obesity: identification, 
assessment and management. 2014. 
22. Accardi, R., et al., Italian version of the laval questionnaire: Validity and reliability. 
Bariatric Surgical Practice and Patient Care, 2017. 12(3): p. 136-141. 
23. Moher, D., et al., Preferred reporting items for systematic reviews and meta-analyses: 
the PRISMA statement. Annals of internal medicine, 2009. 151(4): p. 264. 
24. Google. Google Translate. Available from: https://translate.google.com/. Acessed 
November 11, 2019. 
25. Bond University. Systematic Review Accelerator.; Available from: http://sr-
accelerator.com/#/. Acessed November 11, 2019. 
26. EndNote [computer program]. Version X8, Web of Science Group. 2019. 
27. Covidence systematic review software, Veritas Health Innovation, Melbourne, 
Australia. Available at www.covidence.org. 
28. PLOTCON, WebplotDigitizer. 2017: Oakland, CA. 
29. Academy of Nutrition & Dietetics. Evidence Analysis Manual. Appendix 8: Quality 
Criteria Checklist: Primary Research Available from: 
https://www.andeal.org/evidence-analysis-manual Published 2016. Accessed October 
28, 2019   
20 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
30. Erika Paniago, G., et al., Impact of 6 months of treatment with intragastric balloon on 
body fat and quality of life in obese individuals with metabolic syndrome. Health and 
Quality of Life Outcomes, 2017. 15(1): p. 1-6. 
31. The Cochrane Collaboration, Review Manager [computer program]. Version 5.3. 
2014: Copenhagen: The Nordic Cochrane Centre; . 
32. Higgins, J.P.T., Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. 
ed. Wiley Cochrane Ser., ed. J. Thomas. 2019, Newark: John Wiley & Sons, 
Incorporated. 
33. Tayyem, R.M., C. Obondo, and A. Ali, Short-term outcome and quality of life of 
endoscopically placed gastric balloon and laparoscopic adjustable gastric band. 
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology 
Association, 2011. 17(6): p. 400. 
34. Tayyem, R.M., J.M. Atkinson, and C.R. Martin, Development and validation of a new 
bariatric-specific health-related quality of life instrument ''bariatric and obesity-
specific survey (BOSS)''. Journal of postgraduate medicine, 2014. 60(4): p. 357. 
35. Guedes, E., et al., Impact of a 6-month treatment with intragastric balloon on body 
composition and psychopathological profile in obese individuals with metabolic 
syndrome. Diabetology and Metabolic Syndrome, 2016. 8(1): p. 1-7. 
36. Raftopoulos, I. and A. Giannakou, The Elipse Balloon, a swallowable gastric balloon 
for weight loss not requiring sedation, anesthesia or endoscopy: a pilot study with 12-
month outcomes. Surgery for Obesity and Related Diseases, 2017. 13(7): p. 1174-
1182. 
37. Reimão, S., et al., Improvement of Body Composition and Quality of Life Following 
Intragastric Balloon. Obesity Surgery, 2018. 28(6): p. 1806-1808. 
21 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
38. Ponce, J., B.B. Quebbemann, and E.J. Patterson, Prospective, randomized, 
multicenter study evaluating safety and efficacy of intragastric dual-balloon in 
obesity. Surgery for Obesity and Related Diseases, 2013. 9(2): p. 290-295. 
39. Machytka, E., et al., Elipse, the first procedureless gastric balloon for weight loss: a 
prospective, observational, open-label, multicenter study. Endoscopy, 2017. 49(2): p. 
154. 
40. Guedes, M.R., et al., Changes in Body Adiposity, Dietary Intake, Physical Activity 
and Quality of Life of Obese Individuals Submitted to Intragastric Balloon Therapy 
for 6 Months. Obesity surgery, 2019. 29(3): p. 843. 
41. Alfredo, G., et al., Long-term multiple intragastric balloon treatment—a new strategy 
to treat morbid obese patients refusing surgery: Prospective 6-year follow-up study. 
Surgery for Obesity and Related Diseases, 2014. 10(2): p. 307-311. 
42. Fuller, N., et al., An intragastric balloon in the treatment of obese individuals with 
metabolic syndrome: A randomized controlled study. Obesity, 2013. 21(8): p. 1561-
1570. 
43. Deliopoulou, K., et al., The Impact of Weight Loss on Depression Status in Obese 
Individuals Subjected to Intragastric Balloon Treatment. Obesity Surgery, 2013. 
23(5): p. 669-675. 
44. Castro, M., et al., Efficacy, Safety, and Tolerance of Two Types of Intragastric 
Balloons Placed in Obese Subjects: A Double-Blind Comparative Study. Obesity 
Surgery, 2010. 20(12): p. 1642-1646. 
45. Ahmed, H.O. and R.F. Ezzat, Quality of life of obese patients after treatment with the 
insertion of intra-gastric balloon versus Atkins diet in Sulaimani Governorate, 
Kurdistan Region, Iraq. Annals of medicine and surgery (2012), 2018. 37: p. 42-46. 
22 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
46. Christopher, C.T., et al., Percutaneous Gastrostomy Device for the Treatment of Class 
II and Class III Obesity: Results of a Randomized Controlled Trial. The American 
Journal of Gastroenterology, 2016. 112(3). 
47. Norén, E. and H. Forssell, Aspiration therapy for obesity; a safe and effective 
treatment. BMC obesity, 2016. 3(1). 
48. Moreno, C., et al., Transoral gastroplasty is safe, feasible, and induces significant 
weight loss in morbidly obese patients: results of the second human pilot study. 
Endoscopy, 2008. 40(5): p. 406. 
49. Marinos, G., et al., Weight loss and improved quality of life with a nonsurgical 
endoscopic treatment for obesity: clinical results from a 3- and 6-month study. 
Surgery for Obesity and Related Diseases, 2014. 10(5): p. 929-934. 
50. Lindekilde, N., et al., The impact of bariatric surgery on quality of life: a systematic 
review and meta‐analysis. 2015. p. 639-651. 
51. Dawes, A.J., et al., Mental Health Conditions Among Patients Seeking and 
Undergoing Bariatric Surgery: A Meta-analysis. JAMA, 2016. 315(2): p. 150. 
52. Canetti, L., E. Bachar, and O. Bonne, Deterioration of mental health in bariatric 
surgery after 10 years despite successful weight loss. European journal of clinical 
nutrition, 2016. 70(1): p. 17. 
53. Marshall, S., et al., Does intensive multidisciplinary intervention for adults who elect 
bariatric surgery improve postoperative weight loss, comorbidities, and quality of 
life? A systematic review and meta-analysis Obesity Reviews, 2020. In Press. 
54. Mechanick, J.I., et al., Clinical practice guidelines for the perioperative nutrition, 
metabolic, and nonsurgical support of patients undergoing bariatric procedures–
2019 update: cosponsored by American Association of Clinical 
Endocrinologists/American College of Endocrinology, The Obesity Society, American 
23 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and 
American Society of Anesthesiologists. Surgery for Obesity and Related Diseases, 
2019. 
55. Cuijpers, P., et al., Pre-post effect sizes should be avoided in meta-analyses. 
Epidemiology and psychiatric sciences, 2017. 26(4): p. 364. 
56. Von Elm, E., et al., The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement: guidelines for reporting observational studies. 
Preventive Medicine, 2007. 45(4): p. 247-251. 
57. Allergan. Intragastric Balloon System—Directions For Use (DFU). 2011; Available 
from: http://www.allergan.com.au/Products/Overview.aspx. 
58. Beck, A.T., et al., An inventory for measuring depression. Archives of general 
psychiatry, 1961. 4: p. 561. 
59. Beck, A.T., R.A. Steer, and G.K. Brown, Beck Depression Inventory - Second Edition 
(BDI-II). 1996. 
60. EuroQol Research Foundation. EQ-5D-5L User Guide. 2019  [cited 2020 10.02]; 
Available from: https://euroqol.org/publications/user-guides. 
61. Eypasch, E., et al., Gastrointestinal Quality of Life Index: development, validation 
and application of a new instrument. Br J Surg, 1995. 82(2): p. 216-22. 
62. Zigmond, A.S. and R.P. Snaith, The Hospital Anxiety and Depression Scale. Acta 
Psychiatrica Scandinavica, 1983. 67(6): p. 361-370. 
63. Organization, W.H. WHO Quality of Life-BREF (WHOQOL-BREF). n.d; Available 
from: https://www.who.int/substance_abuse/research_tools/whoqolbref/en/. 
64. Kolotkin, R. IWQOL-Lite Asessing the impact of weight on quality of life in adults. 
2017; Available from: https://www.qualityoflifeconsulting.com/iwqol-lite.html. 
24 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
65. Kolotkin, R.L., S. Head, and A. Brookhart, Construct validity of the impact of weight 
on quality of life questionnaire. Obesity research, 1997(5): p. 434-441. 
66. Ware, J.E., M. Kosinski, and S.D. Keller, A 12-Item Short-Form Health Survey: 
Construction of Scales and Preliminary Tests of Reliability and Validity. Medical 
Care, 1996. 34(3): p. 220-233. 






This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
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Figure 3. Pooled effects of intragastric balloon placement on pre- to postprocedural mental 
health 
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Table 1. Characteristics and outcomes of the 20 included publications which reported quality of life and/or mental health pre and post endoscopy 
bariatric therapies in adults. 
Study design, setting and participants  Endoscopic therapy  Outcomes  
Ahmed et al, 2019 [45]; Prospective study-; 2008-12; 
Iraq; BIB: n= 40, 100%F, µ27y (range: 20-39y), 
BMI µ36 (range: 31–39.9) kg/m2, 0% attrition. 
BIB; Duration of Tx: 6m; Method: inserted under 
sedation, 600mL saline containing 10% methyl blue; 
Follow-up: d7, d14, then monthly.  
Quality of life (6m follow-up): EQ-5D: NR.   
De Castro et al 2010 [44]; Prospective study; 2006-9; 
Spain; BIB: n=15, 67%F, µ45.4±8y, BMI µ44.2±6 
kg/m2. Heliosphere IGB: n=18, 72%F, µ42.7±12y, 
BMI µ44.2±5 kg/m2, 18% attrition. 
BIB; Duration of Tx: 6m; Method: inserted under 
conscious sedation, 700ml saline containing methylene 
blue; Follow-up: monthly.  
Quality of life (6m follow-up): GIQLI score: baseline µ86.9±17. 
Follow-up: µ83.6 ±12. Calculated change: -3.3.  
Heliosphere IGB; Duration of Tx: 6m; Method: 960cm3 
air; Follow-up: monthly.  
Quality of life (6m follow-up): GIGLI score: baseline µ92.2+18. 
Follow-up: µ102.4 ±23. Calculated change: +10.2.  
Deliopoulo et al, 2013 [43]; Prospective study-; 
2009–2010; Greece; IGB: n=100; Depressed group: 
n=65, 100%F, µ37.52 + 11.77y [median: 37, range: 
19-61], µ43.5 + 9.5 kg/m2. Non-depressed group: 
n=35, 100%F, 33.89 + 11.50y [33,18-63], BMI 41.9 
+ 7.4 kg/m2, 0% attrition. 
BioEnterics IGB; Duration of Tx: 6m; Method: inserted 
under sedation; Follow-up: monthly + 24h telephone 
helpline.   
Depression symptoms (6m follow-up): BDI-II baseline: µ20.3 + 
8.5 [range: 10-54]. Follow-up: µ7.9 + 5.6 [range: 0-26], p<0.0001. 
Calculated change = -12.4.     
Familiari et al, 2011. [12]; Prospective study-; 2007- 
2010; Italy & Belgium; TOGA: n=67; follow-up 
n=53; 70%F, µ41.0+9.7y, BMI µ41.5+3.6 kg/m2, 
21% attrition. 
TOGA sleeve stapler & restrictor systems; Method: 
inserted under sedation, sleeve stapler device; Follow-
up: monthly.   
Quality of Life (12m follow-up): SF-36v2 & IWQOL-Lite: p= < 
0.001.     
Fiorillo et al, 2020 [13]; Retrospective study; 2016-
2018; France; ESG: n=84;; 70%F, µ41y (range: 35-
43y), BMI µ39.5 (range: 36.7-44.7) kg/m2, 50% 
attrition.  
OverStitch, Apollo Endo-surgery; Method: flexible 
endoscopic suturing system; Follow-up: 6m.   
Quality of Life (6m follow-up): GIQLI scores: Baseline: 105. 
Follow-up: 119. Calculated change: +14 (range: 3-24). Data 
reported graphically. 
Fuller et al, 2013 [42]; RCT-; 2008-2010; Australia; 
Treatment: IGB: n= 31, 68% F, µ43y, 36 kg/m2. 
Control: Lifestyle modification n=35, 66% F, 
µ48.1y, 36.7 kg/m2, 26% attrition (ITT used) 
Orbera; Duration of Tx: 12m; Method: inserted using 
standard protocol [57], 450-700ml saline; Follow-up: 
6m, every 3m.  
Quality of Life (6m follow-up): IWQOL-Lite: Baseline: 60.7+16. 
Calculated change: 20.9.   
Alfredo et al, 2014 [41]; Prospective study; Italy; 
IGB: n=83, 77%F, µ37.4y, BMI 43.74 kg/m2, 41% 
attrition.  
BIB; Duration of Tx: 6m; Method: Propofol sedation, 
500mL saline. Multiple IGB: Reintroduced after weight 
gain >50%, n=83 had 2nd IGB, n=22 (18%) had 3rd 
IGB, n=1 (1.2%) had 4th IGB; Follow-up: 12m, 6y.  
Quality of life (76m follow-up) n=64/83: SF-12: Baseline: 
Physical: µ40 + SE (4), Mental health: µ50 + SE (4). Follow-up: 
Physical: µ85 + SE (8), calculated change: +45, Mental health: µ78 
+ SE (7), calculated change: +28, p=<0.001. Data reported 
graphically.    
29 
This is a post-peer-review, pre-copyedit version of an article published in Obesity Surgery. 
The final authenticated version is available online at: https://doi.org/10.1007/s11695-020-04860-2 
Guedes et al, 2019. [40]; Prospective study-; 2016-
2018; Brazil; IGB: n=42; 76%F, µ37.60±1.28y, 
BMI µ35.15±0.41kg/m2, 0% attrition. 
Orbera or Spatz; Duration of Tx: 6m; Method: inserted 
under sedation, 600-700mL saline, containing 4% 
methylene blue; Follow-up: 6m, monthly.    
Quality of Life (6m follow-up): SF-36 mean + IQR score: 
Baseline: general health: (72, 57-82), MH (52, 40-72). Follow-up: 
general health (82, 72-92, p=0.0002), MH (76, 68-84, p=0.0003). 
Calculated change: general health: +10, MH: +24.  
Marinos et al, 2014. [49]; Prospective study; 
Australia; Transpyloric shuttle 3m: n=10, 90%F, 
µ36.3+11.4y, BMI µ34+1.3kg/m2. Transpyloric 
Shuttle 6m: n=10, 90%F, µ45+8.3y, BMI 
µ37.9+7.3kg/m2, 0% attrition. 
TransPyloric Shuttle; Duration of Tx: 3m; Method: 
inserted under sedation; Follow-up: 6m  
Quality of Life (6m follow-up):   
 IWQOL-Lite score: Calculated change: +20.4+14.2.   
TransPyloric Shuttle; Duration of Tx: 6m; Follow-up: 
6m  
Quality of Life (6m follow-up): IWQOL-Lite score: Calculated 
change: + 23.3+20.5.   
Machytka et al, 2017 [39]; Prospective study-; 2014-
2015; Czech Republic & Greece; IGB: n=34; 67%F, 
42+11y (range: 18-59y), BMI 34.8+3.7kg/m2 
(range: 27-40kg/m2), 6% attrition.  
Elipse device; Duration of Tx: 4m (range: standard 117-
141d; experimental 30-141); Method: IGB inside 
capsule, attached to catheter via a patented self-sealing 
valve and swallowed, 550mL of fluid (n=28); Follow-
up: fortnightly. 
Quality of Life (4m follow-up): IWQoL total score (n=26): 
Baseline: µ68. Follow-up µ82+12.2. Calculated change: -14.    
Moreno et al, 2008 [48]; Prospective study; Belgium; 
TOGA: n=11, 64%F, µ44.2+10.7y, BMI 
µ41.6+4.3kg/m2, 0% attrition.   
  
  
TOGA System sleeve stapler; Method: inserted under 
sedation; Follow-up: monthly.    
Quality of Life (6m follow-up): SF-36 total score: Baseline: 96. 
Follow-up: 49.9. Calculated change: -46; IWQOL-Lite domain 
scores: general health (40.4), MH (40). Follow-up: general health 
(56.7), MH (50). Calculated change: general health: +16.3, MH: 
+10.     
Mui et al, 2010 [20]; Prospective study; 2005-2006; 
China; IGB: n=119, 72%F, µ37.8+10y, BMI: 
µ38.4+8.0 kg/m2, (range: 26.5 - 69.1kg/m2), 0% 
attrition. 
BioEnterics IGB; Duration of Tx: 6m; Method: inserted 
& removed by surgical team, µ542.7+28.2mL; Follow-
up: weekly with dietitian for 1m, then monthly.   
  
Quality of life (6m follow-up): SF-36: (Chinese Version): General 
health baseline: µ 40.3+10.5, follow-up: 49.4+11.3, calculated 
change: µ-9.1. MH: baseline: µ43.8+12.4, follow-up: µ47.7+13.3, 
calculated change: µ3.9, (p>0.014).   
Norén& Forssell 2016 [47]; Prospective study; 2012-
2013; Sweden; Aspiration Therapy: n=25, 92%F, 
µ48y, (range: 33-65y), BMI µ39.8+4.3 kg/m2, 20% 
attrition.  
Aspire Assist System; Duration of Tx: 12m (optional 
additional 12m); Method: custom gastrostomy tube 
percutaneously inserted during gastroscopy under 
sedation. Drainage & irrigation of stomach 3x/day; 
Follow-up: 4 in 3m, then every 3m.   
Quality of life (12m follow-up): EQ-5D baseline: µ0.7+0.3, 
follow-up: µ0.9+0.1 (p<0.01), VAS baseline: µ63+15, follow-up: 
µ83+14, (p<0.01).   
Ponce et al, 2012 [38]; RCT; 2010- 2011; USA; IGB: 
n=21, 81%F, µ38.9+9.1y, BMI µ34.7+2.6kg/m2, 5% 
attrition. 
ReShape Duo IGB System; Duration of Tx: 6m; 
Method: 900mL saline; Follow-up: monthly-6m, bi-
weekly-48weeks. 
Quality of Life (6m follow-up): SF-36 domain scores: baseline 
general health (73.9), MH (87.3). Follow-up: general health (80.7), 
MH (86.1). Calculated change: general health +6.8, MH -1.2.   
Reimao, 2018 [37]; Prospective observational study-; 
2014-2016; Brazil; IGB: n=40, 78%F, µ45.3+7.6y 
(range: 25-57y), BMI µ32.9+2.0 kg/m2, 10% 
attrition.  
Orberra IGB; Duration of Tx: 6m; Method: inserted 
under general anaesthesia, 600mL saline and methylene 
blue dye; Follow-up: monthly (nutritionist).   
Quality of life (6m follow-up): SF-36 (validated Portuguese 
version) General Health (%) baseline: µ43, follow-up: µ68, 
calculated change: +25. MH (%) baseline: µ62, follow-up: µ79, 
calculated change: +17. Data reported graphically.    
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Raftopoulos et al, 2017. [36]; Prospective 
observational, nonrandomised study; Greece; IGB: 
n=12, 58%F, µ41y (range: 18-59y), BMI 
µ36.1+3.2kg/m2, 8% attrition 
Elipse Balloon; Duration of Tx: 4m; Method: insertion 
via swallow with water, 550mL water containing citric 
acid/potassium sorbate preservative; Follow-up: 
fortnightly.   
Quality of Life (12m follow-up): IWQOL-Lite score: Baseline 65. 
Follow-up: 58. Calculated change: -7.     
Guedes et al 2017[2], Guedes et al 2016 [35]; 
Prospective observational study-; 2011-2012; Brazil; 
IGB: n=50, 80%F, µ34.6+7.1y, BMI µ40+6.3 
kg/m2, 22% attrition. 
  
Silmed Silicone IGB; Duration of Tx: 6m; Method: 
inserted under sedation, 650mL saline solution (0.9%) 
and 20mL methylene blue solution; Follow-up: weeks 
0, 8,16 & 24.  
Quality of life (6m follow-up): WHOQOL-BREF Physical domain 
baseline; µ54.3+17.9, follow-up; µ67.0+16.2, p<0.01, Psychological 
domain baseline; µ55.9+17.2, follow-up; µ64.5+19.9, p 
0.03. Calculated change: physical: +12.7, psychological: +8.6.   
Depression/Anxiety (6m follow-up): *BDI: Baseline: µ16 
(median), (range: 1-32), follow-up; µ6, (range: 0-45), change: 
µ4.57±10.6, (p=0.0019); HADS-D baseline: µ7 (range: 1-14), 
follow-up: 4 (0-18), change: 1.82+5.16, (p=0.0345).   
Tayyem et al, 2014 [34]; Single centre, prospective 
study-; 2010-2010; Scotland; IGB: n=12, 62%F, 
µ40y, BMI µ55.9kg/m2, attrition unclear.  
BioEnterics IGB (BIB) System; Duration of Tx: 6m; 
Method: inserted under sedation, 600mL saline 
containing methylene blue.   
Quality of Life: SF-36 domain scores: Baseline general health: 29. 
Follow-up:  general health: 63. Calculated change: general health: 
+34.   
Tayyem et al, 2011 [33]; Prospective study; 2008-
2010; IGB: n=17, 65%F, µ40.9y, BMI µ61.4+8.3 
kg/m2, 0% attrition.   
  
BioEnterics IGB (BIB) System; Duration of Tx: 6m; 
Method: inserted under sedation, 600mL saline 
containing methylene blue; Follow-up: quarterly.    
Quality of Life (9m follow-up): SF-36 domain scores: Baseline 
general health: 28. Follow-up: general health: 70. Calculated 
change: general health: +42, p<0.021. Data reported graphically.    
Thompson et al, 2017 [46]; RCT-; 2012-2015; USA; 
Aspiration therapy: n=111, 83%F, µ43.5+10.2y, 
BMI µ42.4+5.0 kg/m2, 26% attrition. 
Aspire Assist System; Duration of Tx: 52w; Method: 
Endoscopically placed percutaneous gastrostomy tube, 
external device for drainage 20mins post-meal; Follow-
up: week 0, 2,6,10,14,20,24,28,32,36,40,44,48 & 52.    
Quality of life (12m follow-up): IWQOL Total Score change: 
µ6.2+13.4.   
BDI: Beck Depression Inventory; BDI-II; Beck Depression Inventory II; BFM: Body fat mass; BMI: body mass index; BW: Body weight; CRP: C-reactive Protein; DBP: 
Diastolic blood pressure; DLD: dyslipidaemia; DM: diabetes mellitus; ED: Eating disorder; EQ-5D: European Quality of life measurement questionnaire; ESL: English as a 
second language; EW: Excess weight; EWL: excess weight loss; FBGL: Fasting blood glucose; GIQLI: Gastrointestinal Quality of Life Index; Hx: history; HDAS-A: 
Hospital Anxiety and Depression Scale (Anxiety score); HDAS-D: Hospital Anxiety and Depression Scale (Depression Score); HTN: hypertension; IBD: inflammatory 
bowel disease; IGB: intragastric balloon; IQR: interquartile range; ITT, intention to treat; IWQOL-Lite: Impact of Weight on QOL-Lite; LDL: low density lipoprotein; 
MH: mental health; MI: myocardial infarction; MS: Metabolic Syndrome; NR: not reported; QOL: quality of life; SBP: Systolic blood pressure; SD: standard deviation; 
SF-12: Quality Metric’s Short Form; SF-36: 36-Item Short-Form Health Survey; TBWL: Total body weight loss; TC: Total Cholesterol; TG: Triglycerides; TOGA: 
transoral gastroplasty; VAS: Visual Analogue Scale; WC: Waist circumference; WL: Weight loss.   
BDI: score decreases [58]  
BDI-II: score decreases [59]  
EQ-5D: score increases[60].   
GIQLI: score increases. 4 is the most desirable option, 0 is the least desirable option [61] 
HDAS: score decreases[62]  IWQOL-BREF: A higher score indicates an improved quality of life [63]  
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IWQOL-Lite: score increases. Scores range from 0 to 100, with 100 representing the best quality of life [64]  
IWQOL: higher scores indicated lower levels of functioning and QOL [65]  
SF-12: score decreases [66]   
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Table S1: Systematic search strategy  
MEDLINE (via PubMed) was searched 21st October 2019 using keywords (title and abstract) and MeSH Terms. Result = 1421 records 
(((("Obesity, Morbid /surgery"[Mesh] OR ("morbid obesity"[tiab] AND surgery[tiab])) OR "Obesity, Morbid /therapy"[Mesh]) OR ("Morbid obesity"[tiab] 
AND therapy[tiab]))) OR ((((((((((((((((((((((((Gastroplasty[Mesh]) OR Gastroplasty[tiab]) OR "Single-Balloon Enteroscopy"[Mesh]) OR "Single-balloon 
enteroscopy"[tiab]) OR "Double-Balloon Enteroscopy"[Mesh]) OR "Double-balloon enteroscopy"[tiab]) OR "Double-balloon enteroscopy"[tiab]) OR 
Bioenterics[tiab]) OR Orbera[tiab]) OR Spatz[tiab]) OR "transpyloric shuttle"[tiab]) OR "endoscopic sleeve gastroplasty"[tiab]) OR "aspire assist"[tiab]) 
OR ((incisionless[tiab]) AND "anastomosis, surgical"[Mesh])) OR "anastomotic system"[tiab]) OR "Balloon Enteroscopy"[Mesh]) OR "balloon 
enteroscopy"[tiab]) OR "Gastric balloon"[tiab]) OR "intragastric balloon*"[tiab]) OR BIB[tiab]) OR IB[tiab]) OR "ESG bariatric"[tiab]) OR "gastric 
bubble"[tiab]) OR "intragastric bubble"[tiab])AND ((((("Quality of life"[Mesh]) OR "quality of life"[tiab]) OR hrql[tiab]) OR qol[tiab]) OR hrqol[tiab]) 
CINAHL (via Ebscohost) was searched on 21st October 2019 using keywords and CINAHL Headings. Results = 109 records 
TI (hrqol) OR AB (hrqol) OR TI (hrql) OR AB (hrql) OR TI ("Quality of Life") OR AB ("Quality of Life") OR MH "Quality of Life" AND TI ("gastric 
bubble") OR AB ("gastric bubble") OR TI (BIB) OR AB (BIB) OR TI ("double-balloon enteroscopy") OR AB ("double-balloon enteroscopy") OR TI 
("Single-balloon enteroscopy") OR AB ("Single-balloon enteroscopy") OR TI ("intragastric balloon") OR AB ("intrgastric balloon") OR TI ("gastric 
balloon") OR AB ("gastric balloon") OR TI ("aspire assist") OR AB ("aspire assist") OR TI ("endoscopic sleeve gastroplasty") OR AB ("endoscopic sleeve 
gastroplasty") OR TI ("transpyloric shuttle") OR AB ("transpyloric shuttle") OR TI (spatz) OR AB (spatz) OR TI (orbera) OR AB (orbera) OR TI 
(Bioenterics) OR AB (Bioenterics) OR TI ("balloon enteroscopy") OR AB ("balloon enteroscopy") OR MH "Balloon Enteroscopy" OR TI (gastroplasty) 
OR AB (gastroplasty) OR MH "Gastroplasty" AND ( TI ("morbid obesity") OR AB ("morbid obesity")) OR (TI (surgery) OR AB (surgery)) OR MH 
"Obesity, Morbid" AND (TI ("therapy") OR AB ("therapy")) 
EMBASE was searched 21st October 2019 for citations from both Embase and MEDLINE using keywords (abstract and title) and Emtree terms Results = 
4066 records 
hrqol:ab,ti OR hrql:ab,ti OR 'quality of life'/exp OR 'quality of life':ab,ti AND bib:ab,ti OR 'gastric bubble':ti,ab OR 'esg bariatric':ti,ab OR ib:ti,ab OR 
'stomach bypass device':ti,ab OR 'intragastric balloon':ti,ab OR 'gastric balloon'/exp OR 'gastric balloon':ti,ab OR 'balloon enteroscopy':ti,ab OR 'balloon 
enteroscopy'/exp OR 'aspire assist':ti,ab OR 'transpyloric shuttle':ti,ab OR orberra:ti,ab OR spatz:ti,ab OR bioenterics.ti,ab OR 'double balloon 
enteroscopy':ti,ab OR 'single balloon enteroscopy':ti,ab OR 'single balloon enteroscopy'/exp OR 'endoscopic sleeve gastroplasty'/exp OR 'endoscopic sleeve 
gastroplasty':ti,ab OR 'obesity therapy':ti,ab OR 'obesity therapy'/exp OR 'stomach bypass device'/exp OR 'morbid obesity':ab,ti OR 'surgery'/exp OR 
'bariatric surgery'/exp OR 'anastomotic system':ti,ab OR 'anastomosis, surgical':ti,ab OR 'anastomosis and surgical':ti,ab OR incisionless:ti,ab 
PsycINFO was searched 22nd October 2019 using keywords (title and abstract) and PsycINFO Terms. Result = 362 records 
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exp Obesity/ and exp Surgery/ OR "morbid obesity".ab,ti. OR surgery.ab,ti. OR therapy.ab,ti OR gastroplasty.ab,ti. OR "Single-Balloon Enteroscopy".ab,ti. 
OR "Double-Balloon Enteroscopy".ab,ti. OR Bioenterics.ab,ti. OR Orbera.ab,ti. OR Spatz.ab,ti. OR "transpyloric shuttle".ab,ti. OR "endoscopic sleeve 
gastroplasty".ab,ti. OR "aspire assist".ab,ti. OR incisionless.ab,ti. OR "anastomosis, surgical".ab,ti. OR "anastomotic system".ab,ti. OR "Balloon 
Enteroscopy".ab,ti. OR "Gastric balloon".ab,ti. OR "intragastric balloon".ab,ti. OR BIB.ab,ti. OR IB.ab,ti. OR "ESG bariatric".ab,ti. OR "gastric 
bubble".ab,ti. OR "intragastric bubble".ab,ti. AND exp *"Quality of Life"/ OR hrql.ab,ti. OR hrqol.ab,ti. OR qol.ab,ti.  
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Table S2: Extended version of characteristics and outcomes of the 20 included publications which reported quality of life and/or mental health pre 
and post endoscopy bariatric therapies in adults.   
Study design, setting and 
participants   
Endoscopic therapy   Outcomes   Comment   
Ahmed et al 2019 (56)  
Prospective 2-arm (1=endoscopic; 
1=Atkins diet) randomised 
descriptive longitudinal study-; 2008-
12.   
Exclusion: psychological problems, 
taking psychotropic drugs, previous 
IB or bariatric surgery, peptic ulcers, 
binge eating disorders.   
Iraq   
BIB: n= 40, 100%F, µ27y (range: 20-
39y), BMI µ36 (range: 31–39.9) 
kg/m2.   
BIB   
Duration of Tx: 6m   
Method: inserted under 
sedation, 600mL saline containing 10% 
methyl blue.   
Follow-up: d7, d14, then monthly.   
  
Quality of life (6m follow-up):   
EQ-5D: NR.    
Weight loss:   
EWL%: 31-35kg (47.5%), p=0.00001   
  
No funding received.    
Author contacted about type of 
QOL tool used; could not 
provide data.    
Participants reported daily 
teasing prior to therapy, afraid 
of media stating risks of 
obesity, obesity made 
participants uneasy socialising 
with friends – narrowed social 
circles and weight as an 
obstacle to obtaining a job.     
De Castro et al 2010 (55)  
Prospective 2-arm (2=endoscopic) 
double-blinded study; 2006-9.   
Exclusion: disease of upper GIT, 




BIB: n=15, 67%F, µ45.4±8y, BMI 
µ44.2±6 kg/m2.   
Heliosphere IGB: n=18, 72%F, 
µ42.7±12y, BMI µ44.2±5 kg/m2.   
BIB   
Duration of Tx: 6m   
Method: inserted under conscious 
sedation, 700ml saline containing 
methylene blue.   
Follow-up: monthly.   
Quality of life (6m follow-up):   
GIQLI score: baseline µ86.9±17. Follow-up: µ83.6 ±12. 
Calculated change: -3.3.   
Weight loss:   
Baseline: µ121+18kg. Calculated change: -13kg.    
EWL%: µ30.2±19%.   
          Adverse events:   
n=3/15 continuous vomiting and dehydration.   
Funded by a FISS grant.   
  
Heliosphere IGB   
Duration of Tx: 6m   
Method: 960cm3 air   
Follow-up: monthly.   
Quality of life (6m follow-up):   
GIGLI score: baseline µ92.2+18. Follow-up: µ102.4 ±23. 
Calculated change: +10.2.   
Weight loss:   
Baseline: µ119+17kg. Calculated change: -13kg.     
EWL%: µ27±16.   
  
Deliopoulo et al 2013 (54)  
Prospective study-; 2009–2010.   
Exclusion: no alcohol, drug problems 
or active psychosis.   
Greece   
IGB: n=100   
BioEnterics IGB  
Duration of Tx: 6m   
Method: inserted under conscious or 
unconscious sedation under endoscopic 
vision.   
Depression symptoms (6m follow-up):    
BDI-II baseline: µ20.3 + 8.5 [range: 10-54]. Follow-up: µ7.9 + 5.6 
[range: 0-26], p<0.0001. Calculated change = -12.4.    
Weight loss (kg):    
Baseline: µ124.7 + 32.3kg. Follow up: µ103.7 + 30.1kg, p= 0.983. 
Calculated change: -21kg.     
No funding received.    
Authors contacted about brand 
of balloon & funding source.   
Theorised self-esteem and 
subjective well-being are 
influenced by poor self-
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Depressed group: n=65 (mild-26, 
moderate-21, severe-18), 100%F, 
µ37.52 + 11.77y [median: 37, range: 
19-61], µ43.5 + 9.5 kg/m2.    
Non-depressed group: n=35, 100%F, 
33.89 + 11.50y [33,18-63], BMI 41.9 
+ 7.4 kg/m2.    
Follow-up: monthly. Dietitian and 24h 
telephone helpline available for 
support.    
EWL%: µ39.6%.     reported physical health and 
body image” than body weight 
itself.    Weight loss (kg):   
Baseline: µ122.3 + 24.2kg. Follow up: µ103.6 + 24.1kg.  
Calculated change = -18.7kg.    
EWL%: µ36.1kg.    
Familiari et al. 2011. (13)  
Prospective single-arm study-; 2007- 
2010.     
Exclusion: BMI >55kg/m2, hiatus 
hernia >2cm, previous bariatric 
surgery, inflammatory disease of 
GIT, pregnancy or breast feeding, 
HIV, esophagitis, alcohol/drug 
addiction, present infection, thyroid 
disease, hx of scleroderma.   
Italy & Belgium.     
TOGA: n=67; follow-up n=53; 
70%F, µ41.0+9.7y,  
 BMI µ41.5+3.6 kg/m2.    
TOGA sleeve stapler & restrictor 
systems.     
Method: inserted under sedation, sleeve 
stapler device.   
Follow-up: monthly.    
   
   
Quality of Life (12m follow-up):    
SF-36v2 & IWQOL-Lite: p= < 0.001.    
Weight loss:    
Baseline: µ116.6+18.5kg. Calculated change: -19+8.5kg.    
EWL%: µ38.7+ 7.1%.    
Comorbidities:    
Baseline: DM n=4/67.   
Follow-up: DM n=3/53 (p=0.0005).     
  
Funding by Satiety Inc.     
n=2 underwent laparoscopic 
bariatric procedures within 
12m-post TOGA.    
Fiorillo et al. 2020 (14)  
Retrospective single-centre study-; 
2016-2018.    
France   
ESG: n=42; follow-up n=23; 16F 
(69.6%), µ41y (range: 35-43y), BMI 
µ39.5 (range: 36.7-44.7) kg/m2.    
  
OverStitch, Apollo Endo-surgery.    
Method: flexible endoscopic suturing 
system.    
Follow-up: 6m.    
QOL (6m follow-up):    
GIQLI scores: Baseline: 105. Follow-up: 119. Calculated change: 
+14 (range: 3-24).    
Data reported graphically.  
Weight loss:   
Baseline: µ115.5+29.6kg.    
EWL%: 39.9 (range: 17.5-58.9) %.    
Comorbidities:     
Baseline: DM: n=2/23, HTN n=3/23, OSA n=5/23.   
Follow-up: DM n=1/23, HTN n=2/23, OSA n=2/23.    
   
Fuller et al 2013 (53)   
RCT-; 2008-2010.   
Exclusion: Conditions increasing the 
risks associated with endoscopy or 
insertion of IGB, inflammation of 
GIT, upper GI bleeding conditions, 
hx of symptoms of oesophageal or GI 
Orbera.    
Duration of Tx: 12m   
Method: inserted using standard 
protocol (61), 450-700ml saline.     
Follow-up: 6m, every 3m.   
12m behavioural modification program 
(diet and exercise).   
QOL (6m follow-up):   
IWQOL-Lite: Baseline: 60.7+16. Calculated change: 20.9.    
Weight loss:   
 Baseline: µ104.6kg. Calculated change: -14.4kg.   
%EWL: µ50.3%.    
Adverse events:    
Funded by a grant to the Boden 
Institute by Allergan Australia 
Pty Ltd.   
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motility disorders, hiatus hernia 
>5cm, structural abnormality of the 
GI tract, prior gastric surgery or IGB, 
or major surgery within 3m, 
cerebrovascular or cardiopulmonary 
disease, uncontrolled BP 
(>160/95 mmHG), epilepsy, T1DM, 
undiagnosed thyroid disease or 
hypothyroidism in which the dose of 
thyroxine replacement has not been 
stable for at least 3m, hepatic or renal 
insufficiency, psychiatric disorder or 
pregnancy.   
Australia   
Treatment: IGB: n= 31, 68% F, µ43y, 
36 kg/m2.    
Control: Lifestyle modification n=35, 
66% F, µ48.1y, 36.7 kg/m2.    
  
Control Group   
T2DM Lifestyle Intervention 
Program.    
12 months, 3 months   
75% nausea/vomiting, 39% reflux, 33% lethargy, 55% abdominal 
pain/cramping in week 1.    
Comorbidities:   
Baseline: metabolic syndrome: 31/31.  
Follow-up: metabolic syndrome: 15/31.    
   
Alfredo et al, 2014 (52)  
Prospective 6y follow-up study.   
Exclusion: Weight loss >5% or 
medication causing weight gain (e.g. 
glucocorticoids or second generation 
anti-psychotic medication).   
Italy   
IGB: n=83, follow-up: n=49, 64F 
(77%), µ37.4y, BMI 43.74 kg/m2.   
  
BIB   
Duration of Tx: 6m   
Method: Propofol sedation administered 
by an anaesthetist, 500mL saline. 
Multiple IGB: Reintroduced after 
weight gain >50%, n=83 had 2nd IGB, 
n=22 (18%) had 3rd IGB, n=1 (1.2%) 
had 4th IGB.    
Follow-up: 12m, 6y.   
Low-calorie diet provided by dietitian.   
   
Weight loss (12m follow-up)   
BMI: 35.9kg/m2, (change: -7.8kg/m2), p=<0.001.   
Quality of life (76m follow-up) n=64/83   
SF-12: Baseline: Physical: µ40 + SE (4), Mental health: µ50 + SE 
(4). Follow-up: Physical: µ85 + SE (8), calculated change: +45, 
Mental health: µ78 + SE (7), calculated change: +28, p=<0.001.    
Data reported graphically.     
Comorbidities:    
Baseline: T2DM: 33/83, HTN: 58/83, OSA: 16/83, p=0.02.     
Follow-up: T2DM: 14/49, HTN: 17/49, OSA: 5/49.  
Data reported graphically.    
Adverse Events:   
1st IGB placement: Nausea, vomiting and epigastric pain µ2.5 d, 
2nd IGB placement: Nausea, vomiting & epigastric pain µ4 d. No 
major complications, IGB removal: n=1 for intolerance.   
  
Guedes et al., 2019. (51)  
Prospective observational study-; 
2016-2018.    
Exclusion: endocrine (DM, 
hypothyroidism, PCOS), AIDS, 
inflammatory conditions, malignant 
Orbera or Spatz   
Duration of Tx: 6m   
Method: inserted under sedation 
by anesthesiologist, 600-700mL saline.  
containing 4% methylene blue.    
Follow-up: 6m, monthly.    
Quality of Life (6m follow-up):    
SF-36 mean + IQR score: Baseline: general health: (72, 57-82), 
MH (52, 40-72), functional capacity (60, 40-85). Follow-up: 
general health (82, 72-92, p=0.0002), MH (76, 68-84, p=0.0003), 
functional capacity (90, 85-95, p=0.0001). Calculated change: 
general health: +10, MH: +24, functional capacity: +30.    
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diseases, autoimmune diseases, CKD, 
HF, hepatic failure disorders, 
medications interfering with 
weight.     
Brazil   
IGB: n=42; 0% attrition, 76%F, 
µ37.60±1.28y, BMI 
µ35.15±0.41kg/m2.    
Individualised low-calorie diet provided 





Weight loss:    
Baseline: µ96±1.9kg. Follow-up: 80.6±2.0kg. Calculated change: 
-15.4+1.5kg.    
EWL%: 56.04±4.90%, p= <0.0001.    
Comorbidities:    
Baseline: HTN: n=6/42, dyslipidaemia: n=32/42.     
Marinos et al., 2014. (60)  
Prospective open-label study.    
Exclusion: positive helicobacter 
pylori, insulin-dependent DM, active 
gastric ulcer.    
Australia.     
Transpyloric shuttle 3m: n=10, 
90%F, µ36.3+11.4y, BMI 
µ34+1.3kg/m2.   
Transpyloric Shuttle 6m: n=10, 
90%F, µ45+8.3y, BMI 
µ37.9+7.3kg/m2.    
   
TransPyloric Shuttle    
Duration of Tx: 3m   
Method: inserted under sedation.     
Follow-up: 6m   
Quality of Life (6m follow-up):    
IWQOL-Lite score: Calculated change: +20.4+14.2.    
Weight loss:    
Baseline: µ98+8.1kg.    
EWL%: 25.1+14%.    
Funding by BAROnova Inc.   
Author contacted about QOL 
data – awaiting response.    
TransPyloric Shuttle    
Duration of Tx: 6m   
Follow-up: 6m   
  
Quality of Life (6m follow-up):    
IWQOL-Lite score: Calculated change: + 23.3+20.5.    
Weight loss:    
Baseline: µ103.8+28.3kg.    
EWL%: 41+21.1%.    
Adverse events:    
Mucosal erosion: n=15/20, gastric ulcers: n=10/20.   
Funding by BAROnova Inc.   
Author contacted about QOL 
data – awaiting response.    
Machytka, E et al, 2017 (50)  
Prospective, observational and open 
label design-; 2014-2015.   
Exclusion: small bowel obstruction, 
signs or symptoms of oesophageal, 
gastric or intestinal disease, IBD, 
cancer or a known large hiatal hernia. 
More than 1 laparoscopic or 
abdominal surgery and surgery in 
>12m, hx of smoking.   
Czech Republic & Greece.    
IGB: n=34; follow-up n=32, 23F 
(67%), 42+11y (range: 18-59y), BMI 
34.8+3.7kg/m2 (range: 27-
40kg/m2).    
Elipse device    
Duration of Tx: 4m (range: standard 
117-141d; experimental 30-141).    
Method: IGB folded inside capsule, 
attached to catheter via a patented self-
sealing valve and swallowed, 550mL of 
fluid (n=28). Experimental IGB made 
from radiopaque film, slightly smaller 
capsules for ease of swallowing 
(n=6).     
Follow-up: fortnightly.  
Nutritional counselling fortnightly & 
encouraged to follow a high protein 
1000-1200 Calories/day diet.   
Quality of Life (4m follow-up):   
IWQoL total score (n=26): Baseline: µ68. Follow-up µ82+12.2. 
Calculated change: -14. Physical: baseline: µ68+12.9 follow-up: 
µ82, calculated change: +14.    
Weight loss (n=26):   
BMI: Follow-up: µ-3.9+3.1kg/m2 (-5.2 CL, -2.6 CI), p<0.001.      
TBWL%: follow-up µ10+6.6%, (7.3, 12.7), p<0.001.   
Adverse events (n=26):   
 n=24/26, abdominal distension: n=1/26, abdominal pain: n=7/26, 
constipation: n=5/26, diarrhea: n=4/26, GERD: n=3/26, nausea: 
15/26, vomiting: n=18/26.     
Comorbidities (change at follow-up) (n=26):   
HBA1c (mg/dL): µ -0.2+0.2% (-0.2,-0.009), LDL: -  µ9.7+27.6 (-
21.4,2.0), TG: µ-16.4+50.9 (-37.9, 5.1), SBP: µ-9.6+16.1 (-16.2, -
2.9), DBP:µ-5.8+7.9 (-9.0,-2.5).    
Two authors received 
consulting fees 
from Allurion Technologies, 1 
author is a consultant and 3 
authors are shareholders in the 
company.   
Moreno et al., 2008(59)  
Prospective single-arm study.    
TOGA System sleeve stapler.    
Method: inserted under sedation.    
Quality of Life (6m follow-up):    Funding by Satiety Inc.    
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Exclusion: hx of IBD, pregnancy, 
cancer, etc.   
Belgium    
TOGA: n=11, 64%F, µ44.2+10.7y, 
BMI µ41.6+4.3kg/m2.    
   
   
Follow-up: monthly.  
Diet and exercise guideline booklet 
provided at follow-up.       
SF-36 total score: Baseline: 96. Follow-up: 49.9. Calculated 
change: -46.     
IWQOL-Lite domain scores: physical function (38.9), general 
health (40.4), MH (40). Follow-up: physical functioning (54.7), 
general health (56.7), MH (50). Calculated change: physical 
functioning: +15.8, general health: +16.3, MH: +10.    
Weight loss:    
Baseline: µ119.8+22.2kg. Calculated change: -24kg.    
EWL%: 46%, p= <0.05.    
Adverse events:   
Epigastric pain: n=11/11, esophagitis: n=2/11, throat pain: n=3/11, 
nausea: n=2/11, mild dysphagia: n=3/11.    
Comorbidities:    
Baseline: T2DM: n=4/11, HTN: n=6/11, hyperlipidaemia: 4/11.    
Mui et al 2010 (22)  
Prospective study-; 2005-2006.   
China    
IGB: n=119, 
86F (72.3%), µ37.8+10y, BMI: 
µ38.4+8.0 kg/m2, (range: 26.5 - 
69.1kg/m2).    
   
BioEnterics IGB    
Duration of Tx: 6m   
Method: inserted & removed by 
surgical team, µ542.7+28.2mL.     
Follow-up: weekly with dietitian for 
1m, then monthly.    
   
Quality of life (6m follow-up)   
SF-36: (Chinese Version): Physical functioning baseline: 
µ28.8+19, follow-up: µ39.8+15.2, calculated change: -11, 
(p>0.0005). General health baseline: µ 40.3+10.5, follow-up: 
49.4+11.3, calculated change: µ-9.1. MH: baseline: µ43.8+12.4, 
follow-up: µ47.7+13.3, calculated change: µ3.9, (p>0.014).    
Weight loss(kg):   
Baseline: µ103.7+24.1kg, (range: 63.8-183.6kg). Follow-up: µ 
91.3±23kg. Calculated change: -µ12.4+6.9kg, p<0.0005.    
EWL%: µ45.1±35.3%.    
Adverse events:   
Intolerance (early removal):  n=4/119, anaemia: n=1/119, 
hypokalaemia: n=1/119.   
Comorbidities:   
MS Baseline; µ 42.9%, follow-up: µ15.1%,  
FBG (mmol/l) baseline: µ6.1+2.0 follow-up µ5.3+1.7,  
HBA1c (%) baseline: µ7.4+1.6, follow-up: µ5.8+0.7,(p<0.0005),  
TC (mmol/l) baseline; µ5.1+0.9,follow-up; µ4.7+0.9 (p<0.0005), 
TG (mmol/l ) baseline; µ1.7+1.0 follow-up µ1.3+0.7,  (p<0.0005),  
SBP (mmHg) baseline; µ145.4+19.7 follow-up; 
133.2+20.9  (p<0.005),  
DBP baseline; µ84.3+12.6, follow-up; µ78.8+15.4  (p<0.005),  
CRP (mg/l) baseline; µ6.9±6, follow-up; µ6.1+6.5 (p<0.024).  
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Norén, E.; Forssell, H, 2016 (58)  
Prospective observational study-; 
2012-2013.    
Sweden   
Exclusion: MI <3m, known 
malignancy, chronic liver or kidney 
disease major upper GI surgery, 
psychiatric disease including 
substance abuse, ED, mental 
retardation or other intellectual 
disability.    
Aspiration Therapy: n=25, follow-up 
n=20; 23F (92%), µ48y, (range: 33-
65y), BMI µ39.8+4.3 kg/m2.    
Aspire Assist System.    
Duration of Tx: 12m (participants had 
option to continue therapy for an 
additional 12m).    
Method: custom gastrostomy tube (A-
tube, Aspire Bariatrics) percutaneously 
inserted during gastroscopy under 
sedation. Drainage & irrigation of the 
stomach performed 3x/day (76% 
patients aspirated 3x/day), 20mins post-
meal for 1-2y. Diet + exercise 
counselling during Tx.    
Follow-up: 4 in 3m, then every 3m.    
Cognitive behavioural therapy, 8 
sessions.  
Quality of life (12m follow-up):       
EQ-5D baseline: µ0.7+0.3, follow-up: µ0.9+0.1 (p<0.01), VAS 
baseline: µ63+15, follow-up: µ83+14, (p<0.01).    
Weight loss (kg):   
Baseline: µ107.4+18.7kg, follow-up: µ88.4+16.9kg, calculated 
change: -µ19kg (p<0.01).    
EWL%: µ44.5+28.8%.     
Adverse events:   
moderate pain: n=13/25, severe pain: n=3/25, hospital admission 
(suspected leakage): n=2/25, intra-abdominal leakage at 
gastrostomy site: n=1/25, stoma site related problems: n=3/25.   
Comorbidities: (n=20)    
Baseline: T2DM: n=7/20, HTN: n=8/20, high cholesterol n=2/20, 
mood disorder n=6/20, GERD n=2/20.   
Follow-up: T2DM n=5/20, HTN n=7/20, high cholesterol 
n=2/20, mood disorder n=6/20, GERD n=3/20.   
HbA1c (mmol/mol) Baseline; µ47 median (IQR 43-66), follow-
up; 42, (36-64), (p<0.03),  
Funding support by Scientific 
Committee of Blekinge County 
Council.   
Initial exploratory safety study. 
   
Ponce et al., 2012 (49)  
RCT-; 2010- 2011.    
Exclusion: peptic ulcer, erosive 
esophagitis, hiatus hernia >2cm, 
etc.     
USA   
IGB: n=21, follow-up n=20, 17F 
(81%), µ38.9+9.1y, BMI 
µ34.7+2.6kg/m2.    
  
ReShape Duo IGB System.     
Duration of Tx: 6m   
Method: 900mL saline.     
Follow-up: monthly-6m, bi-weekly-
48weeks.  
Diet and exercise counselling.   
Quality of Life (6m follow-up):    
SF-36 domain scores: baseline physical functioning (83.6), 
general health (73.9), MH (87.3). Follow-up: physical functioning 
(96.9), general health (80.7), MH (86.1). Calculated change: 
physical: +13.3, general health +6.8, MH -1.2.    
Weight loss:     
Baseline: µ100.8+11.6kg.    
EWL%: 31.8%.    
Adverse events:    
Hypoxia: n=1/21, nausea: n=4/21.    
Funding by and written with 
assistance 
from ReShape Medical Inc.   
Contacted author for numerical 
data, unable to provide.    
Reimao, 2018 (48)  
Prospective observational study-; 
2014-2016.   
Exclusion: any contradictions to IGB 
or impossibility of follow-up.    
Brazil   
IGB: n=36 analysed (40 included); 
follow-up n=38, 28F (77.7%), 
µ45.3+7.6y (range: 25-57y), BMI 
µ32.9+2.0 kg/m2.   
   
Orberra IGB.   
Duration of Tx: 6m   
Method: inserted under general 
anaesthesia, 600mL saline and 
methylene blue dye.   
Follow-up: monthly (nutritionist).    
Hypocaloric diet (1000kcal/day), 120 
min/week physical activity suggested. 
Caloric intake estimated by five 24-h 
dietary recall on non-consecutive days 
for 1m.   
Quality of life (6m follow-up):   
SF-36 (validated Portuguese version) Physical Aspects (%) 
baseline: µ70, follow-up: 92, calculated change: +22. General 
Health (%) baseline: µ43, follow-up: µ68, calculated change: +25. 
MH (%) baseline: µ62, follow-up: µ79, calculated change: +17.    
Data reported graphically.     
Weight loss:   
Baseline; µ89.8+12.1kg, Follow-up: µ77.5+14.6kg, calculated 
change: -µ12.3kg, (p<0.001).    
TBWL%: 13.7%.    
Adverse events:   
Author contacted about 
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   Fungal colonisation of IGB: 2/40.   
Raftopoulos et al., 2017. (47)  
Prospective observational, 
nonrandomised study.    
Exclusion: HF, COPD, previous 
bariatric therapy, pregnancy, etc.   
Greece.   
IGB: n=12, 58%F, µ41y (range: 18-
59y), BMI µ36.1+3.2kg/m2.    
   
   
Elipse Balloon.     
Duration of Tx: 4m.    
Method: insertion via swallow with 
water, 550mL water containing citric 
acid/potassium sorbate preservative.   
Follow-up: fortnightly.  
Diet and exercise program.    
Quality of Life (12m follow-up):    
IWQOL-Lite score: Baseline 65. Follow-up: 58. Calculated 
change: -7.     
Weight loss:    
Baseline: µ103.5+15.8kg. Calculated change: -6.5kg.    
EWL%: 17.6%.     
Adverse events:    
Nausea: n=4/12, vomiting: n=1/12, abdominal cramping: n=1/12, 
GERD: n=2/12, constipation: n=2/12.    
Raftopoulos received 
consulting fees 
for Allurion Technologies.     
   
Guedes et al 2017(2),Guedes et al 
2016 (46)  
Prospective observational study-; 
2011-2012.   
Exclusion: T1/T2DM, pregnancy, 
previous gastric surgery, hiatal hernia 
>5cm, clotting disorders, potentially 
bleeding gastrointestinal lesions, 
alcoholism or use of drugs, previous 
hx of psychiatric disorders, current 
use of anti-depressants or other 
psychiatric drug, and weight loss 
treatment within the previous 6m.   
Brazil   
IGB: n=50, follow-up n=39, 40F 
(80%), µ34.6+7.1y, BMI µ40+6.3 
kg/m2.    
   
Silmed Silicone IGB.   
Duration of Tx: 6m    
Method: inserted under sedation, 
650mL saline solution (0.9%) and 
20mL methylene blue solution.    
Follow-up: weeks 0, 8,16 & 24.   
Quality of life (6m follow-up):   
WHOQOL-BREF Physical domain baseline; µ54.3+17.9 (14.2-
92.8), follow-up; µ67.0+16.2, (25.0-100.0), p<0.01, 
Psychological domain baseline; µ55.9+17.2 (12.5-91.6), follow-
up; µ64.5+19.9 (16.6-95.8), p 0.03.    
Calculated change: physical: +12.7, psychological: +8.6.    
Weight loss:   
Calculated change: µ11.7+9.6, (p<0.0001)   
BMI: µ -4.4+3.5kg/m2 (p<0.0001).    
Adverse events:    
Gastric intolerance: n=4/50, balloon rupture: n=5/50, uterus 
cancer: n=1/50.   
Funding by Silmed Silicone 
Instrumental 
Medico Ciurgico Hospital Ltda, 
Rio de Janeiro, RJ, Brazil. The 
funding body had no role in 
study design, collection, 
analysis, interpretation of data 
or writing the manuscript.   
Depression/Anxiety (6m follow-up):   
*BDI: Baseline: µ16 (median), (range: 1-32), follow-up; µ6, 
(range: 0-45), change: µ4.57±10.6, (p=0.0019).    
HADS-D baseline: µ7 (range: 1-14), follow-up: 4 (0-18), change: 
1.82+5.16, (p=0.0345).    
  
Tayyem, Atkinson & Martin, 
2014 (45)  
Single centre, prospective study-; 
2010-2010.    
Exclusion: no written consent, ESL.    
Scotland.    
IGB: n=12, 62%F, µ40y, BMI 
µ55.9kg/m2.    
BioEnterics IGB (BIB) System    
Duration of Tx: 6m   
Method: inserted under sedation, 
600mL saline containing methylene 
blue.    
Quality of Life:    
SF-36 domain scores: Baseline physical functioning: 36.5, general 
health: 29. Follow-up: physical functioning: 57.5, general health: 
63. Calculated change: physical functioning: +21, general health: 
+34.   
Weight loss:       
Baseline: µ156+21kg. Calculated change: -15+12kg.      
EWL%: 25.4%.     
Comorbidities:    
Authors contacted about IGB 
data; data provided.    
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Baseline depression: n=10/12.    
Tayyem, Obondo Ali, 2011 (44)  
Prospective longitudinal study-; 
2008-2010.    
Exclusion: previous bariatric 
surgery/abdominal surgery, hiatus 
hernia, peptic ulcers, unfit for 
surgery/anaesthesia.    
Scotland.   
IGB: n=17, 65%F, µ40.9y, BMI 
µ61.4+8.3 kg/m2.    
  
   
BioEnterics IGB (BIB) System    
Duration of Tx: 6m   
Method: inserted under sedation, 
600mL saline containing methylene 
blue.    
Follow-up: quarterly.     
  
Quality of Life (9m follow-up):    
SF-36 domain scores: Baseline physical functioning: 35, general 
health: 28. Follow-up: physical functioning: 72, general health: 
70. Calculated change: physical functioning: +37, p<0.041, 
general health: +42, p<0.021.    
Data reported graphically.     
Weight loss:    
Baseline: µ172+19.5kg. Calculated change: -µ25.6+14.4kg, 
p<0.001.      
EWL%: 26.2+14%.     
Adverse events:    
Nausea: n=4/17, vomiting: n=4/17.    
Comorbidities:    
Baseline: DM: n=3/17, HTN: n=6/17, hyperlipidaemia: n=3/17, 
IHD: n=4/17, OSA: n=2/17.   
Follow-up: 
DM 1/17, HTN 1/17, hyperlipidaemia 1/17, IHD 2/17, OSA 1/17.   
Author contacted for numerical 
values of graphs.   
Orlistat 120mg prescribed 3/d 
for weight loss, access to 
helpline and referrals to 
gym/slimming activities 
provided pre-procedure.  
Thompson et al, 2017 (57)  
RCT-; 2012-2015.    
Exclusion: hx of gastrointestinal 
disease or previous abdominal 
surgery increasing the risk of A-tube 
placement, previous bariatric surgery, 
chronic abdominal pain, serious 
CVD, medication significantly 
impacting on weight loss or weight 
gain and hx of major depressive, 
psychiatric or eating disorders.   
USA   
Aspiration therapy: n=82 (n=26 
withdrew pre-enrolment, n=29 
dropped out), 68F (82.9%), 
µ43.5+10.2y, BMI µ42.4+5.0 
kg/m2.   
   
 Aspire Assist System   
Duration of Tx: 52w   
Method: Endoscopically placed 
percutaneous gastrostomy tube (15cm 
fenestrated intragastric portion) with an 
external device to facilitate drainage of 
30% of calories consumed 20mins post-
meal.   
Follow-up: week 0, 
2,6,10,14,20,24,28,32,36,40,44,48 & 
52.  
Diet and lifestyle counselling 
program.      
Quality of life (12m follow-up):   
IWQOL Total Score change: µ6.2+13.4, Physical Function score 
change: 7.1+15.5.     
Weight loss:   
Baseline: 116.9±21.2, Change: µ14.2+11.3kg.    
EBWL%: µ37.2+27.5%.    
Adverse Events:    
Abdominal pain within 4 weeks: n=42/111, peristomal granulation 
tissue: n=45/111, peristomal irritation: n=19/111, 
nausea/vomiting: n=19/111, intermittent abdominal discomfort: 
n=18/111, peristomal bacterial infection: n=15/111, dyspepsia: 
n=7/111, peristomal inflammation: n=6/111.    
Serious adverse events: n=4/111, severe abdominal pain: n=1/111, 
peritonitis: n=1/111, pre-pyloric ulcer: n=1/111, a-tube 
replacement (skin port malfunction): n=1/111.  
Comorbidities:    
HbA1c baseline; µ5.7+0.5, change: 0.36% (p<0.0001), TG 
baseline: µ140.8+81.7, change: 9.9% (p=0.02), 
SBP baseline: µ12.2+13.3, change: 1.2% (p=0.38), 
DBP baseline; µ78.8+8.9, change: 2.6%(p=0.06), 
LDL; baseline µ115.4+32.8, change: 4.2% (p=0.06%)   
Funded by Aspire Bariatrics - 
performed statistical analysis & 
assisted preparing the 
manuscript.   
Participants were permitted to 
continue in the study for an 
additional 48m if they lost and 
maintained at least 10% of their 
body weight from baseline.   
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Footnote:   
BDI: Beck Depression Inventory; BDI-II: Beck Depression Inventory II;  BFM: Body fat mass; BMI: body mass index; BW: Body weight; CRP: C-reactive 
Protein; DBP: Diastolic blood pressure; DLD: dyslipidaemia; DM: diabetes mellitus; ED: Eating disorder; EQ-5D: European Quality of life measurement 
questionnaire; ESL: English as a second language; EW: Excess weight; EWL: excess weight loss; FBGL: Fasting blood glucose; GIQLI: Gastrointestinal 
Quality of Life Index; Hx: history; HDAS-A: Hospital Anxiety and Depression Scale (Anxiety score); HDAS-D: Hospital Anxiety and Depression Scale 
(Depression Score); HTN: hypertension; IBD: inflammatory bowel disease; IGB: intragastric balloon; IQR: interquartile range; IWQOL-Lite: Impact of 
Weight on QOL-Lite; LDL: low density lipoprotein; MH: mental health; MI: myocardial infarction; MS: Metabolic Syndrome; NR: not reported; QOL: 
quality of life; SBP: Systolic blood pressure; SD: standard deviation; SF-12: Quality Metric’s Short Form; SF-36: 36-Item Short-Form Health Survey; 
TBWL: Total body weight loss; TC: Total Cholesterol; TG: Triglycerides; TOGA: transoral gastroplasty; VAS: Visual Analogue Scale; WC: Waist 
circumference; WL: Weight loss.   
QOL/Mental health assessment tools (indication of improvement):   
BDI: score decreases [58]  
BDI-II: score decreases [59]  
EQ-5D: score increases[60]  GIQLI: score increases. 4 is the most desirable option, 0 is the least desirable option [61] 
HDAS: score decreases[62]  
IWQOL-BREF- A higher score indicates an improved quality of life [63]  
IWQOL-Lite: score increases. Scores range from 0 to 100, with 100 representing the best quality of life [64] 
IWQOL- higher scores indicated lower levels of functioning and QOL [65]  
SF-12: score decreases [66]  
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Table S3: Risk of bias assessments and justifications using Academy of Nutrition and Dietetics Quality Criteria Checklist.   
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Table S4: GRADE assessment of the confidence in the body of evidence 
Question: What is the effect of endoscopic bariatric procedures on post-procedure QoL and mental health of adult patients? (in comparison to pre-procedural 
QoL and mental health).  
Certainty assessment  № of patients  Effect  
Certainty  № of 
studies  Study design  
Risk of 








(95% CI)  
Quality of Life (QOL) (follow up: range 4 months to 76 months; assessed with: SF-36, EQ-5D, GIQLI, IWQOL-BREF, IWQOL-Lite, SF-12; Scale 
from: 0 to 100)   
19   Observational 
studies   
Seriousa   not serious   not serious   not serious  Strong 
association   
768  654   SMD 0.83 







Mental Health (follow up: mean 6 months; assessed with: BDI, SF-36 Anxiety, HDAS-A, HDAS-D; Scale from: 7.9 to 84)   
8  Observational 
studies   
Very 
seriousb   
Very seriousc   not serious   Seriousa,c  Strong 
association   
409   363  SMD 0.41 






Very LOW  
CI: Confidence interval; SMD: Standardised mean difference; SD: Standard deviation  
Explanations  
a.  Primary research outcome and patient centred outcome.  
b. Confounding variables not accounted for.  
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c. Heterogeneity was 92% indicating serious imprecision and may have been the result of the type of tool used to assess mental health and/or the amount of 
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